Patient with Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis, Acute Renal Failure, and Coronavirus Disease-19 Pneumonia: A Diagnostic and Therapeutic Challenge by Gerasimovska-Kitanovska, Biljana et al.
542 https://www.id-press.eu/mjms/index
Scientific Foundation SPIROSKI, Skopje, Republic of Macedonia
Open Access Macedonian Journal of Medical Sciences. 2020 Nov 20; 8(T1):542-547.
https://doi.org/10.3889/oamjms.2020.5510
eISSN: 1857-9655
Category: T1 - Thematic Issue “Coronavirus Disease (COVID-19)”
Section: Case Report in Internal Medicine
Patient with Antineutrophil Cytoplasmic Antibody Associated 
Small Vessel Vasculitis, Acute Renal Failure, and Coronavirus 
Disease-19 Pneumonia: A Diagnostic and Therapeutic Challenge
Biljana Gerasimovska-Kitanovska1*, Gjulshen Selim1, Zvezdana Petronijevik1, Blagica Pecanova2, Gjorgi Stojchev2, 
Natasha Eftimovska-Otovic3, Marija Zdravevska4, Elena Jovanovska-Janeva4, Dubravka Antova5, Elena Curakova6
1Department of Internal Medicine, University Clinic of Nephrology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, 
Republic of Macedonia; 2General Hospital, Strumica, Republic of Macedonia; 3Department of Internal Medicine, General City 
Hospital, Skopje, Republic of Macedonia; 4Department of Internal Medicine, University Clinic of Pulmonology and Allergology, 
Medical Faculty, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia; 5Department of Internal Medicine, University 
Clinic of Rheumatology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, Republic of Macedonia; 6Department of 
Internal Medicine, University Clinic of Gastroenterohepatology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, 
Republic of Macedonia
Abstract
BACKGROUND: Antineutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV) has a predilection for the 
kidney and more than three quarters of patients have renal involvement with rapidly progressive glomerulonephritis. 
Small-vessel systemic vasculitis may present as pulmonary-renal syndrome and is characterized by necrotizing 
glomerulonephritis and pulmonary hemorrhage. Diagnosis and therapy for AAV in coronavirus disease (COVID) 
COVID-19 pandemic require multi-disciplinary collaboration due to the affection of multiple systems and risks 
associated with immunosuppressive medications.
CASE REPORT: A 69-year-old non-smoker, non-diabetic female presented in the outpatient unit at the department 
of pulmonology with dry cough, malaise, and sub-febrile temperature, lasting for 1 month. The patient had a high 
suspicion of severe pulmonary-renal syndrome, ANCA-AAV, and acute renal failure requiring hemodialysis. She was 
treated with corticosteroids, cyclophosphamide, and plasma exchange. The treatment led to temporary improvement. 
Infections with COVID-19, Enterococcus in the urine, and Acinetobacter in the tracheal aspirate further complicated 
the clinical picture and despite antibiotic treatment, use of tocilizumab and convalescent plasma, the outcome was 
lethal.
CONCLUSION: It is important to establish the diagnosis and distinguish accurately between vasculitis and infection 
to provide adequate and timely therapy.
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Introduction
Antineutrophil cytoplasmatic antibody (ANCA)-
associated vasculitis (AAV) is a rare group of multisystem 
disorders, affecting 13–25 people per million population 
in Europe [1]. It is characterized by inflammation, 
destruction of small and medium-sized blood vessels, 
and presence of circulating ANCA’s. Clinical disease 
phenotype includes granulomatosis with polyangiitis, 
microscopic polyangiitis, eosinophilic granulomatosis 
with polyangiitis, and renal-limited vasculitis [2]. ANCA-
AAV has a predilection for the kidney and more than 
three quarters of patients have renal involvement with 
rapidly progressive glomerulonephritis [3]. Small-vessel 
systemic vasculitis may present as pulmonary – 
renal syndrome and is characterized by necrotizing 
glomerulonephritis and pulmonary hemorrhage [4].
Diagnosis of a patient with de-novo ANCA-
AAV during coronavirus disease (COVID)-19 pandemic 
is a challenge [5]. Clinical presentation of patients with 
AAV may overlap with manifestations of COVID-19 
infection [6]. Pulmonary affection and acute kidney injury 
may occur as a result of AAV or as a presentation of 
COVID-19 infection [7]. Furthermore, cytokine-release 
syndrome, as a systemic inflammatory response 
which may occur in COVID-19 disease, may mimic 
vasculitis [8]. It is important to distinguish accurately 
between vasculitis and infection to provide adequate 
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and timely therapy. Therapy for AAV in COVID-19 
requires multi-disciplinary collaboration due to the risks 
associated with immunosuppressive medications.
Case Report
A 69-year-old non-smoker, non-diabetic female, 
presented in the outpatient unit at the department of 
pulmonology with dry cough, malaise, and sub-febrile 
temperature, lasting for 1 month. She was treated 
with a combination of two antibiotics (azithromycin 
and ceftriaxone) without improvement of the situation. 
There was no positive family history. She gave a history 
of allergy to non-steroidal anti-inflammatory drug and a 
history of sensorineural hearing loss, needing a hearing 
aid for 2 years. Dry, age-related macular degeneration 
was diagnosed in 2017 and she had a history of 
pneumonia in 2017 and 2019. Chest examination at 
check-up revealed an auscultation finding of vesicular 
respiration with bronchial crackling sounds bilaterally in 
the basal parts.
Due to persistent symptoms, a chest X-ray and 
computed tomography (CT) scan were performed with 
a finding of parenchymal consolidation on the basis 
of the right lobe in continuity with the lower part of the 
right hilum and pronounced peri-bronchial changes 
bilaterally. The heart, aorta, and major blood vessels 
and central pulmonary arteries were patent without 
evident emboli. Four tests for COVID-19 were made, 
all negative.
The patient was admitted in the department 
of pulmonology. The microbiological results from 
sputum were negative and tests such as anti-nuclear 
antibodies HEp-2 (indirect fluorescence assay), anti-
double-stranded deoxyribonucleic acid, and c-ANCA 
were all negative. p-ANCA immunological test was 
positive, pneumonia panel plus test was negative, 
hantavirus immunoglobulin (Ig) IgM was negative, rapid 
test for Mycobacterium tuberculosis was negative on 
two separate occasions, and the Löwenstein–Jensen 
medium was negative. Procalcitonine level was 
0.4 ng/ml (ref. value 0, 15 ng/ml).
Due to the rapid increase of serum creatinine 
from 65 umol/l to 695 umol/L and serum urea 13 mmol/L 
(normal range of serum creatinine 45–109 umol/L and 
serum urea 2, 7–7, 8 mmol/L) on the 7th day of the 
hospitalization, a femoral venous catheter was placed, 
and the next day the first dialysis was performed. 
Urinary analysis showed proteins and blood in the 
urine. Affection of multiple systems and ANCA positivity 
implied the use of Birmingham vasculitis activity score 
(BVAS) as an index of severity of disease and it was 17.
All efforts to obtain tissue biopsy failed. 
Invasive lung investigations were not possible due to 
the overall estimation of risk as very high. Renal biopsy 
was not possible due to prolonged bleeding time. 
Nasal endoscopy was indicated. Unfortunately, no 
granulomatous disease-associated lesions in the nasal 
cavities were found and biopsy was not done.
The patient was transferred to our department 
of nephrology on the 9th day of the hospitalization at 
the department of pulmonology, with high suspicion 
of pulmonary-renal syndrome, ANCA-AAV, and acute 
renal failure requiring hemodialysis.
On transfer, the patient still complained of 
shortness of breath and had hematuria. General 
examination of the patient revealed an alert and 
conscious patient with pale skin. On admission, the 
patient was hypertensive (165/90 mmHg), tachycardic 
(123 bpm), and hypoxic (oxygen saturation on room 
air 85%) and had no visible swelling on the lower 
extremities. Chest examination revealed an auscultation 
finding of vesicular respiration with bronchial crackling 
sounds bilaterally in the basal parts. Examination of 
other systems was unremarkable. The BVAS score in 
our department was calculated as 33.
The blood tests on admission demonstrated 
renal impairment with a creatinine of 364 umol/L, an 
ongoing acute inflammatory response with C-reactive 
protein (CRP) 205 mg/L, leukocytosis 17.5 (109/L), 
lymphocytopenia 8.2%, anemia red blood cell (RBC), 
hemoglobin (HGB), (RBC 2.5; HGB 72; hematocrit 0.2), 
serum albumins 27 g/L, and total protein 56 g/L. 
Urinalysis demonstrated blood and protein on dipstick 
testing. Proteinuria of 3.5 g/dU was confirmed. 
Immunological status of the patient: IgM, IgE, IgG, IgA, 
C3, and C4 levels were normal. Anti-glioblastoma was 
negative. COVID-19 polymerase chain reaction (PCR) 
test at admission at the department was negative. Viral 
markers for hepatitis B and C were negative.
An ultrasound of the kidneys and urogenital tract 
was performed with the following finding: Both kidneys 
with normal ultrasound shape and placement with no 
pathological findings, urinary bladder unremarkable.
A CT lung scan on the day of admission in 
our department was indicated and revealed an evident 
progression of finding demonstrated with diffuse 
centrilobular ground-glass opacities dominantly in 
upper lobes and an alveolar consolidation, as well 
as in apicobasal and in the right basal segments with 
patchy nodular lesions. On the right side, there was an 
anterior subsegmental and posterobasal consolidation 
and small pleural effusion. Findings were suggestive 
for alveolar hemorrhage consistent with autoimmune 
disease-vasculitis (Figure 1).
Immediately upon transfer of the patient at the 
department of nephrology, patients’ oxygen saturation 
dropped to 70%. Oxygen therapy was commenced 
and continued throughout her stay in the hospital. 
After obtaining the CT scan finding, induction therapy 
was started for the treatment of ANCA positive AAV. 
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Several diagnostic tests were done out of the hospital 
building. The patient received intravenous pulse 
methylprednisolone therapy in a dosage of 500 mg 
per day for 3 days, continued with oral prednisolone, 
slowly tapered to 60 mg per day. An intravenous drip 
of cyclophosphamide 500 mg was administered. 
Due to the alveolar hemorrhage, plasmapheresis 
treatment was started. Seven sessions were planned, 
but only 4 were performed due to further aggravation 
of the situation. Plasmaphereses and hemodialysis 
sessions were performed on an alternate day. With 
this treatment and oxygen support, saturation started 
to rise and reached 90%. In addition to this treatment 
an antihypertensive drug (a calcium antagonist) and an 
inhibitor of the gastric proton pump were administered. 
Urine culture revealed Enterococcus and treatment was 
started with amp. tazobactam a 4, 5 g/12 h, according 
to an antibiogram.
Figure 1: Findings of computed tomography lung scan at admission 
in the department of nephrology were suggestive for diffuse alveolar 
hemorrhage
Due to activated fibrinolysis (elevated levels of 
D-dimer - 9024), low molecular dose of heparin (amp. 
Clexane a 40 mg per day) was started. Two units of 
RBCs were administered during the hospitalization.
After 11 days of hospitalization in our unit, the 
inflammatory markers of the patient were in decline: 
CRP 20 mg/L; white blood cell 11, 5, but there was 
persistent anemia even after transfusion with two doses 
of RBC (HGB 95; RBC 3, 2). During the hospitalization 
period, the patient was afebrile and circulatory stable.
After 12 days of hospital treatment and a 
requirement to repeat the cycle of cyclophosphamide at 
the 14th day, and a newly stated complaint of pharyngeal 
dryness and drop of HGB to 72 g/l, a control nasal swab 
for PCR test was taken for severe acute respiratory 
syndrome coronavirus 2 (SARS-COV-2), which turned 
out positive. Serological IgM and IgG tests for SARS-
COV-2 were negative. Plasma exchanges were 
discontinued due to the co-infection with COVID-19.
According to the protocol, the patient was 
transferred to a COVID-19 hospital. Discharge 
diagnosis included pulmorenal syndrome, acute renal 
failure stage 3, treatment with hemodialysis, ANCA-
AAV, alveolar hemorrhage treated with plasmapheresis, 
anemic syndrome, urinary infection with Enterococcus, 
and infection with COVID-19.
The patient was first transferred to the 
infectious diseases unit in the general city hospital 
and diagnosed with COVID-19 pneumonia. Another 
reverse transcription PCR (RT-PCR) test for SARS-
COV-2 taken upon admission was also positive. Initial 
laboratory tests were made on admission and revealed 
persistent anemia and hypoalbuminemia.
There the hemodialysis treatment continued. 
CT angiography of the pulmonary truncus showed 
bilateral diffuse zones of interstitial consolidation 
(Figure 2). Multiple lymph nodes were seen in the 
mediastinum. Visualization of the main pulmonary 
truncus (Figure 3) and pulmonary arteries showed 
no alterations in the hemodynamic flow and no endo-
luminal thrombotic masses. No alterations of the blood 
flow were seen in the segmental pulmonary branches, 
but subsegmental branches were not visible because of 
massive consolidation.
Figure 2: Bilateral diffuse zones of consolidation
Pulmonary X-ray showed massive zones of 
parenchymal consolidations in the apical, middle, and 
basal parts of both lungs.
Because of the severe general health 
condition, the patient was transferred to the intensive 
care unit, was intubated, and put on a mechanical 
ventilator. She was oligoanuric and under continuous 
inotrope stimulation. The laboratory tests revealed an 
increase in interleukin 6 (IL-6) (30 pg/ml); ferritin> 612; 
and procalcitonin 2, 13 ng/ml.
Acinetobacter was identified in the tracheal 
aspirate. She was treated with triple antibiotic 
therapy (Meropenem, Linezolid, and Colistin). An 
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infectious disease specialist was consulted and 
tocilizumab was added to the medication list. The 
patient was also treated with packed RBCs, fresh 
frozen plasma, convalescent plasma, ozone therapy, 
anticoagulant, and gastroprotective therapy. In spite 
of treatment and used measures for cardiopulmonary 
resuscitation, death occurred on the 33rd day of her 
first hospitalization.
Figure 3: Absence of thrombotic masses
Discussion
Our patient had a pulmonary-renal syndrome 
and severe ANCA-associated renal involvement, 
complicated with COVID-19 pneumonia.
The exact clinical phenotype of the AAV 
could not be determined, since tissue biopsy was 
cancelled, due to the severity of the general condition 
and prolonged bleeding time. A 3-year history of 
sensorineural loss of hearing, macular degeneration, 
pneumonia, and allergies may imply isolated affection 
of several organs as part of vasculitis. There were no 
signs of highly active disease in her medical history. 
Although an uncommon finding, these findings were 
suggestive of microscopic polyangiitis in the absence 
of granulomas and more destructive local changes [9].
For at least a month before hospitalization, 
there were non-specific constitutional presentations 
such as malaise, low-grade temperature, and diarrhea. 
Progression of the pulmonary and kidney injury, 
with alveolar hemorrhage and rapid progressive 
glomerulonephritis, together with the myeloperoxidase 
(MPO) positivity and high score of disease activity BVAS, 
led to diagnosis of AAV. Microscopic polyangiitis was the 
most probable phenotype in our patient. This finding is not 
unexpected, according to a study which reported that in 
a 20-year population-based cohort of patients with AAV-
glomerulonephritis, 65% had microscopic polyangiitis, 
and 74% were MPO-ANCA positive [10].
Recent reports showed that ANCA antibodies 
are not only a biomarker of AAV but are involved in the 
pathogenesis of the renal involvement in AAV. Binding 
of MPO or proteinase 3 antibodies to autoantigens 
activates neutrophils, that degranulate and release 
reactive oxygen species [11]. Neutrophil extracellular 
traps (NETs) are released to contain infections, but 
if they are not properly regulated, they damage the 
endothelium and activate complement, thus provoking 
inflammation and microvascular thrombosis, explained 
as ANCA-cytokine sequence theory [12], [13]. 
Unregulated NETs are also involved in COVID-19 
pneumonia and lead to a very fast progression of lung 
destruction [14].
According to the grading recommended by the 
European vasculitis study group, the patient had a high 
index of activity of the disease, with life-threatening 
diffuse alveolar hemorrhage [15]. Severity of disease 
implied immediate commencement of therapy. 
Standard of care for induction therapy in severe 
AAV includes a combination of glucocorticoids with 
either cyclophosphamide or rituximab [2].  Although 
autoimmune patients receiving immunosuppressive 
therapy may be prone to COVID-19 infection, it is 
contraindicated to delay therapy [16]. The management 
of glomerular diseases in the COVID-19 era is 
changing, and there are issues whether intravenous 
cyclophosphamide should be substituted with peroral 
or rituximab should not be used at all due to long-
term depletion of B cells [17]. There are recently some 
case reports where rituximab was used successfully 
in patients with AAV [18]. The most recent paper 
for treatment of AAV during COVID pandemics 
recommends plasma exchange, oral glucocorticoids, 
and intravenous cyclophosphamide 500 mg every 2–3 
weeks in 6 doses for COVID-19 negative patients, with 
several options in COVID-19 positive patients [19].
Single intravenous dose of cyclophosphamide 
and pulse methylprednisolone for 3 days was 
administered in our patient. Plasma exchange was 
instituted based on the findings of serum creatinine 
above 500 µmol/l and diffuse intraalveolar hemorrhage 
on CT scan, according to the recommendations of the 
MEPEX trial [20]. Plasma exchange removes the pro-
inflammatory cytokines, complement, and coagulation 
factors, and dilutes ANCA titers, and may decrease 
progression to end-stage renal disease [21].
Inflammatory markers, such as CRP, were 
very high at the beginning of the hospitalization and 
decreased after induction therapy with corticosteroids 
and cyclophosphamide. The clinical condition of the 
patient improved significantly.
Later on in the hospitalization, nasal RT-PCR 
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SARS-COV 2 test was positive, and COVID-19 
pneumonia soon emerged. We found only one report of 
false-positive SARS COV 2 RT-PCR test in a patient with 
AAV, potentially due to cross-reactivity [22]. This was 
not the case with our patient because a positive RT PCR 
test was confirmed twice and the disease progressed 
with worsening of the clinical and radiological features.
There is a link between infection and 
autoimmunity – a higher disease activity may predispose 
to developing infections. We believe that the high 
disease activity index predisposed our patient to infection 
with COVID-19, as well as to urinary infection with 
Enterobacter. Worsening of the condition was confirmed 
by an increase in the inflammatory markers, CRP and 
procalcitonin, and high IL6. Procalcitonin is normal in 
patients with autoimmune disease and when higher 
levels are confirmed, it is associated with infection [23]. 
IL 6, CRP, erythrocyte sedimentation rate, serum ferritin 
were positively associated with the severity of COVID-
19, as suggested in literature [24]. High circulating level 
of D-dimers correlated with the inflammatory markers, 
representing a hypercoagulable state, associated with 
the AAV and also with COVID-19 infection [25], [26].
COVID-19 may be responsible for cytokine 
release syndrome (CRS), as a systemic inflammatory 
response [27]. SARS-CoV-2 binds to alveolar epithelial 
cells and results in the release of a large number of 
cytokines, including IL-6. Treatment of the cytokine 
storm has become an important part of rescuing severe 
COVID-19 patients. Tocilizumab as a IL-6 receptor 
blocker was used as salvage therapy in this patient. 
Tocilizumab was tried in patients with a severe form of 
COVID-19 and cytokine storm yet with no significant 
difference in survival [28].
Although radiological findings of nodules, 
consolidation, and ground-glass opacities were consistent 
first with alveolar hemorrhage in vasculitis, the findings 
progressed into massive zones of consolidation at the 
next radiological imaging (CT angiography) which was 
highly suggestive of COVID-19 pneumonia, confirmed 
by two positive SARS COV2 PCR tests [29].
One of the diagnostic challenges in COVID-19 
infection is that it may provoke acute kidney injury and may 
mimic vasculitis. It was reported that 36.6% of patients 
hospitalized for COVID-19 had acute kidney injury, with 
14.4% requiring a registered respiratory therapist. Acute 
renal failure was registered in patients with respiratory 
failure on mechanical ventilation and was a predictor of 
poor outcome [30]. Renal failure may be due to prerenal 
failure and collapsing glomerulopathy [31]. Recent 
reports object to the SARS-COV2 nephropathy as a 
separate entity, as there was an absence of viral genetic 
material in renal biopsy specimens and no histologic 
proof for cytopathic effects of the virus [32].
Unfortunately, the severe form of AAV, renal 
failure, and infections, despite all therapeutic efforts, 
were predictors of a poor outcome in the patient.
Conclusion
ANCA positive vasculitis is a rare disease 
which needs fast and prompt diagnosis and responds 
well to aggressive treatment with plasmapheresis, pulse 
dose of corticosteroids, and immunosuppressive drugs. 
COVID-19 infection is still a rather new and unknown 
disease, but the CRS that it causes can have a lethal 
outcome in the complications of the primary disease. 
Infections are common in immune-compromised 
patients and the risk is increased with every prolonged 
stay in the intensive care unit. In COVID-19 pandemic, 
it is important to diagnose AAV timely and to provide 
induction therapy as well as to provide treatment for 
concurrent infections.
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